NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) — Denmark-based Vilacto Bio Inc. (OTC QB: VIBI) is happy to announce that the company has decided to introduce 2 new products and present them for the market later this summer/fall. The company will present one product for people with psoriasis and one product for people suffering from diabetes, especially skin issues related to diabetes.
The 2 new products are the result of a significant amount of testing and great customer feedback with the above-mentioned issues. Regarding psoriasis we have learned that patients with this condition are seeing results after a few days’ use. Furthermore, some patients have expanded the periods between regular medical treatments when they are using the Vilact skin cream with the patented ingredient Lactoactive.
But also, when it comes to diabetes, there has been overwhelming feedback. With the cooperation of Danish podiatrists, the Vilact skin cream has helped a large number of patients with issues related to diabetes, and in numerous cases has helped patients get of rid of complicated skin issues.
We believe the secret behind the success of these patients is the Lactoactive particles. The Lactoactive compound is a powerful mix of proteins, vitamins, grow factors and immune factors customized into Nanoparticles for better penetrating the skin and giving their effect, this effect is not only on the skin tissue but deeper as well. The company’s process creates nanoparticles and we believe that the ingredient increases the potency delivered to skin cells.
“We are hoping with the introduction of these new products that people suffering psoriasis and diabetes related skin disorders can have an alternative to the stronger drugs on the market – keeping in mind that what we get from nature sometimes can be more effective with less side effects,” said CEO Gert Andersen. “These products are also expected to have a huge benefit for the company and show the public that the company stands apart from the competition on skincare,” continued Mr. Andersen.
About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.
Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain “forward-looking” statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
Vilacto Bio Inc.
The Seagram Building
375 Park Avenue, Suite 2607
New York City, NY 10152
Gert Andersen
Phone: +1 646-893-7895
info@vilactobio.com
www.vilactobio.com